Table 1 Patient characteristics
Patient ID | Sex | Age | Histology | Stage at enrollment | ECOG* | Expression | Therapy Sequence | Time between the treatment modalities (days) | Response to the conventional treatment (RECIST) | Time to progression from Chemotherapy (days) | Time to progression from Immunotherapy (days) | Survival from Diagnosis (days) | Survival from Immunotherapy (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 61 | Sq/Ad | IIIB (T4,N2) | 1 | HER-2 (grade 3) MAGE1 (grade 5) | CT - IT | 77 | Partial Response | 138 | 47 | 258 | 84 |
2 | M | 66 | Ad | IIIB (T2,N3) | 2 | WT1 (grade 4) CEA (grade 6) | CT - IT - XRT | 38; 3 | Stable disease | 112 | 60 | 358 | 198 |
3 | M | 59 | Ad | IIIB (T4,N2) | 1 | CEA (grade 7) | CT - XRT - IT | 30; 52 | Stable disease | 231 | 82 | 276 | 112 |
4 | F | 63 | IMA | IV (T4,N2,M1)# | 2 | WT1 (grade 2) CEA (grade 7) HER-2 (grade 1) | CT - IT - CT | 45; 56 | Stable disease | 64 | 1 | 329 | 82 |
5 | F | 50 | Sq | IIIB (T4,N2) | 1 | CEA (grade 3) HER-2 (grade 2) | CT - XRT - IT | 51; 56 | Partial Response | 200 | 22 | 560 | 277 |